These studies indicate that the enzymatic action of NQO1 using β-Lap treatment prevents high-salt diet- or cisplatin-induced renal failure, and that this effect is mediated by reduced NADPH oxidase (NOX) activity through cellular NADPH/NADP regulation. The gene discussed is FMO5; the disease is kidney failure.